Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Transgenic GroupTSE:2342 -4.50%60 Days Inventory is 82.83 as of Mar. 2026, which is 40% above its 10-year median of 59.05. GuruFocus rates TSE:2342 with a GF Score™ of 60/100 and a GF Value™ of 円257.97 (Modestly Undervalued). The stock has 4 warning signs investors should review. Among 638 Biotechnology companies, Transgenic Group ranks better than 76.18% on this metric.
The historical rank and industry rank for Transgenic Group's Days Inventory or its related term are showing as below:
TSE:2342'
s Days Inventory Range Over the Past 10 Years
Min: 26.54 Med: 59.05 Max: 84.19
Current: 84.19
During the past 13 years, Transgenic Group's highest Days Inventory was 84.19. The lowest was 26.54. And the median was 59.05.
TSE:2342's Days Inventory is ranked better than 76.18% of 638
companies
in the Biotechnology industry
Industry Median: 183.195
vs TSE:2342: 84.19
Transgenic Group's Days Inventory
increased
from Mar. 2025 (76.42) to Mar. 2026 (82.83).
It might indicate that Transgenic Group's sales slowed down.
Inventory Turnover measures how fast the company turns over its inventory within a year.
Transgenic Group's Inventory Turnover for the
six
months ended in Mar. 2026 was 2.20.
Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Transgenic Group's Inventory-to-Revenue for the
six
months ended in Mar. 2026 was 0.37.
Transgenic Group (TSE:2342) Days Inventory Explanation
Days Inventory indicates the liquidity of the inventory. Generally, a lower Days Inventory is preferred as it indicates a shorter duration to clear off the inventory. An increase of the ratio may indicate the company's sales slowed. Similar ratios related to Days Inventory are:
1. Inventory Turnover measures how fast the company turns over its inventory within a year.
Transgenic Group's Inventory Turnover for the
six
months ended in Mar. 2026 is calculated as
2. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Transgenic Group's Inventory to Revenue for the
six
months ended in Mar. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
A lot of business are seasonable. It makes more sense to compare Days Inventory from the same period in the previous year instead of from the previous quarter.
Transgenic Group Days Inventory Related Terms
Transgenic Group Days Inventory Historical Data
* Premium members only.
The historical data trend for Transgenic Group's Days Inventory can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TSE:2342 vs VRTX, REGN, ALNY: Days Inventory Comparison
For the Biotechnology subindustry, Transgenic Group's Days Inventory, along with its competitors' market caps and Days Inventory data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Transgenic Group Days Inventory vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Transgenic Group's Days Inventory distribution charts can be found below:
* The bar in red indicates where Transgenic Group's Days Inventory falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Transgenic Group (TSE:2342) has a Days Inventory of 82.83 as of Mar. 2026. Days inventory represents the average amount of days a company holds inventory before selling it. View historical data on Transgenic Group and its competitors. This is 40% above median its historical median of 59.05. Over the past decade, Transgenic Group's Days Inventory has ranged from 26.54 to 84.19. According to the industry distribution chart, Transgenic Group ranks #152 out of 638 companies in the Biotechnology industry, placing it in the top 23.8%.
Is Transgenic Group's Days Inventory too high?
Transgenic Group's current Days Inventory of 82.83 is 40% above median its 10-year median of 59.05. Over the past 10 years, this metric has ranged from a low of 26.54 to a high of 84.19. The Biotechnology industry median Days Inventory is 183.20. Transgenic Group's value of 82.83 is 54.8% below this industry median. Based on the distribution chart, Transgenic Group ranks #152 out of 638 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Transgenic Group has a GF Score™ of 60/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Transgenic Group's Days Inventory compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Transgenic Group ranks #152 out of 638 companies for Days Inventory. This places Transgenic Group in the top 24% of its industry — outperforming the majority of peers. The industry median Days Inventory is 183.20. Transgenic Group's value of 82.83 is 54.8% below this benchmark. Historically, Transgenic Group's own Days Inventory has ranged from 26.54 to 84.19 over the past decade. While the company's 10-year median is 59.05 vs. the industry median of 183.20, Transgenic Group has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Inventory for a Biotechnology company?
The median Days Inventory among Biotechnology companies is 183.20, based on 638 companies in the industry. Companies in the top quartile (top 25%) have a Days Inventory significantly above this median, while those in the bottom quartile fall well below. However, Days Inventory should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Transgenic Group's current Days Inventory of 82.83 is 54.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Inventory mean?
A high Days Inventory can signal that a stock is expensive relative to its fundamentals. Days inventory represents the average amount of days a company holds inventory before selling it. View historical data on Transgenic Group and its competitors. For the Biotechnology industry, the median Days Inventory is 183.20 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Transgenic Group's current Days Inventory is 82.83, which is 40% above median its own 10-year median of 59.05. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Transgenic Group stock overvalued right now?
Based on GuruFocus' analysis, Transgenic Group (TSE:2342) is currently considered Modestly Undervalued. The stock's GF Value™ is 円257.97, compared to a current price of 円212.00 — trading 17.8% below its estimated fair value. The current Days Inventory is 82.83, which is 40% above median its 10-year median of 59.05 and 54.8% below the Biotechnology industry median of 183.20. Transgenic Group's overall GF Score™ is 60/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Inventory calculated?
Days Inventory is calculated from a company's financial statements. For Transgenic Group (TSE:2342), the current Days Inventory is 82.83 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Transgenic Group (TSE:2342) Overvalued in 2026?
Based on GuruFocus' analysis, Transgenic Group stock appears to be undervalued.
The current stock price of 円212.00 is trading 17.8% below its estimated GF Value™ of 円257.97.
GuruFocus considers Transgenic Group to be Modestly Undervalued.
Key valuation signals for TSE:2342:
Days Inventory: 82.83 (40% above median its 10-year median of 59.05)
GF Value™: 円257.97 vs. price of 円212.00 (17.8% below fair value)
Industry Position: 54.8% below the Biotechnology median (#152 of 638)
No single metric tells the full story. See the TSE:2342 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Transgenic Group Inc formerly Trans Genic Inc is engaged in offering assistance of non-clinical experiments using large animals and general rearing management work, and non-clinical trial service using large animals. The company has two segments: Drug discovery support business, and Investment and consulting business.
60GF Score
Get the complete analysis for TSE:2342
Days Inventory is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:2342 has been successfully added to your 
